Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab for Cancer-Related Cachexia in Pancreatic Cancer
NCT00060502Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2003
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial in cachexia comparing Infliximab + Gemcitabine with Placebo + Gemcitabine (2 arms). Primary endpoint: Change in Lean Body Mass at 8 weeks. Started Apr 2003; status: completed.
02
Drugs
infliximab
03
Conditions
cachexia
Beyond the preview
Go deeper on NCT00060502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00060502.